Galderma Group AG
🇨🇭Switzerland
Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT02918721
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
A Treatment for Severe Inflammatory Acne Subjects
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 186
- Registration Number
- NCT02899000
- Locations
- 🇺🇸
Galderma Laboratories, LP, Fort Worth, Texas, United States
A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 127
- Registration Number
- NCT02755545
- Locations
- 🇺🇸
Stephens & Associates, Inc. Texas Research Center, Richardson, Texas, United States
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 67
- Registration Number
- NCT02735421
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT02718118
- Locations
- 🇺🇸
Marina Peredo, MD, PC, Smithtown, New York, United States
🇺🇸AboutSkin Dermatology and DermSurgery, Greenwood Village, Colorado, United States
🇺🇸Skin Research Institute, Coral Gables, Florida, United States
Emervel for the Correction of Lower Face Wrinkles & Folds
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 30
- Registration Number
- NCT02718040
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 22
- Registration Number
- NCT02705664
- Locations
- 🇮🇸
Principal Investigator, Reykjavik, Iceland
Injection Technique Assessment of Restylane Silk With Lidocaine for Lip Augmentation
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT02703948
- Locations
- 🇺🇸
United States, Florida, Miami, Florida, United States
🇺🇸United States, Georgia, Roswell, Georgia, United States
🇺🇸United States, California, San Diego, California, United States
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 20
- Registration Number
- NCT02679911
Metvix Daylight PDT in Actinic Keratosis
Completed
- Conditions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 406
- Registration Number
- NCT02674048
- Locations
- 🇮🇹
Italy, L'Aquila, Italy
🇫🇷France, Pontoise, France
🇳🇱Alkmaar, Alkmaar, Netherlands
© Copyright 2024. All Rights Reserved by MedPath